Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) announced that CEO Manuel Aivado will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 1:30 p.m. ET in Miami, FL. The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days thereafter.

Aileron focuses on chemoprotection in oncology, aiming to enhance chemotherapy safety and effectiveness. Their lead product, ALRN-6924, is a dual inhibitor designed to protect healthy cells from chemotherapy damage while targeting cancer cells.

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL.

A live webcast of the event will be available under the Investors & Media section of the company's website at investors.aileronrx.com. A replay of the webcast will be available on the Aileron website for approximately for 30 days following the presentation.

About Aileron Therapeutics
Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy.

Investor Contact:	Media Contact:
Stern Investor Relations	Liz Melone
Alexander Lobo	617-256-6622
alex.lobo@sternir.com	lmelone@aileronrx.com

FAQ

When will Aileron Therapeutics present at the H.C. Wainwright Global Investment Conference?

Aileron Therapeutics will present on May 25, 2022, at 1:30 p.m. ET.

Where can I watch the Aileron Therapeutics conference presentation?

The conference presentation can be watched via a live webcast on the Aileron website under the Investors & Media section.

What is ALRN-6924 and how does it work?

ALRN-6924 is a first-in-class MDM2/MDMX dual inhibitor designed to activate p53, protecting healthy cells from chemotherapy while targeting cancer cells.

What is the goal of Aileron Therapeutics?

Aileron Therapeutics aims to make chemotherapy safer and more effective, ultimately saving more patients' lives.

What is unique about ALRN-6924 in clinical development?

ALRN-6924 is the only reported chemoprotective agent using a biomarker strategy focused on treating patients with p53-mutated cancers.